Compare EPR Properties (EPR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPR Properties vs IDEXX Laboratories, Inc. — how do they compare? EPR Properties trades at $54.74 (market cap $4.17B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 9.7× EPR Properties's market cap, and EPR Properties pays a 6.84% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold EPR Properties for 46 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| EPR | IDXX | |
|---|---|---|
Market Cap | $4.17B | $40.43B |
Volume | 992,716 | 692,164 |
Sector | Real Estate | Health |
52-Week High | $64.32 | $766.68 |
52-Week Low | $48.71 | $504.70 |
Typical Hold Time | 46 Days | 46 Days |
Enterprise Value | $7.68B | $41.32B |
Dividend Yield | 6.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $54.74, up 1.22% today, with a bearish technical signal despite oversold RSI readings. The REIT reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026, with Q3 2026 results pending. Fundamentals show strong profitability with a 37.66% net income margin and a 6.5% dividend yield, supported by $421M in operating cash flow for 2025. Recent news highlights its appeal as a high-yield monthly dividend stock for retirees, with diversification into theme parks and fitness.
The outlook is cautiously optimistic, with a consensus price target of $65.50 implying 20% upside, though technical weakness and a projected net cash flow decline in 2026 pose risks. Investment opportunities include undervaluation relative to peers and resilient tenant performance, while risks involve interest rate sensitivity and execution of diversification strategy amid economic uncertainty.
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EPR Properties
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
